$3.08-1.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Company outlook: revenue of $350M to $370M for Fiscal year 2026 — down 11.6% on a year earlier ($407.3M)
Just reported
From Ardelyx, Inc.'s results release of November 3, 2026; its quarterly report has since been filed.
Actual
$127.7M
+16% y/y
+5.6% q/q
Guided
—
No guide given
Actual
$0.00
Guided
—
No guide given
Actual
$4M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $127.7M | $110.3M | +15.70% |
| Profit | -$737K | -$969K | +23.94% |
| Profit per share | $0.00 | $0.00 | — |
| Free Cash Flow | $2.2M | $209K | +938.76% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Ardelyx, Inc. reported on November 3, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with partners to develop and commercialize its products outside of the United States.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Ardelyx, Inc.’s Item 2.02 8-K filed November 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.